AUG 11, 2020 1:29 PM PDT

FDA Approves New Opioid for Short-Term Use

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has announced the approval of Olinvyk (oliceridine), a new opioid that can help manage moderate to severe acute pain in adults. 

To test the drug, researchers enrolled 1,535 patients with moderate to severe acute pain in randomized, placebo-controlled, open-label trials. Administered to patients having undergone bunion or abdominal surgery, patients on the drug reported decreased pain when compared to those taking the placebo. 

Approved for both inpatient and outpatient procedures, the drug is only available for short-term usage. Meanwhile, its maximum approved dose is 27mg, and its target market is high-risk patients, such as the elderly, those who are obese, or have renal problems. 

Overall, the new drug has a similar safety profile to other opioids, and the FDA warns potential users and medical practitioners alike of its potential for abuse. Nevertheless, like other opioids, its most common side effects include nausea, vomiting, dizziness, headaches, and constipation. The FDA also notes that the drug should not be given to patients with significant respiratory depression and acute or severe bronchial asthma in an unmonitored setting without equipment for emergency resuscitation. 

“Addressing the opioid crisis remains a top priority for the FDA. We will continue to do everything we can to reduce the number of Americans who are addicted to opioids and cut the rate of new addiction through a number of cross-agency initiatives,” says Douglas Throckmorton M.D., deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research. 

“Importantly, the FDA will only approve new drug applications, including those for opioid medications, following a rigorous review to evaluate the risks and benefits and ultimate determination that the data support safety and effectiveness. Of note, this particular medication is only indicated for use in a controlled clinical setting, meaning under medical supervision and not for use in a take-home prescription.”

 

Sources: BioworldFDA

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 14, 2022
Clinical & Molecular DX
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
JUL 14, 2022
Emerging Research Could Soon Solve the Parkinson's Disease Diagnosis Challenge
Parkinson’s disease is a brain disorder with symptoms that begin gradually and worsen over time. Symptoms of Parki ...
JUL 25, 2022
Cardiology
Drug that Can Help Men Live Longer?
JUL 25, 2022
Drug that Can Help Men Live Longer?
A new study from the University of Virginia School of Medicine and recently published in Science discusses how the loss ...
AUG 21, 2022
Drug Discovery & Development
Eczema Drug Helps Increase Covid-19 Survival Rates, Clinical Study Suggests
AUG 21, 2022
Eczema Drug Helps Increase Covid-19 Survival Rates, Clinical Study Suggests
In a recent study published in Open Forum Infectious Diseases, a clinical study led by the University of Virginia (UVA) ...
SEP 07, 2022
Drug Discovery & Development
Perfusion Media Survey Panel: Overview From an Expert
SEP 07, 2022
Perfusion Media Survey Panel: Overview From an Expert
Achieving high cell densities in long-term cultures is often a challenge facing bioprocessing manufacturers, and one tha ...
SEP 11, 2022
Drug Discovery & Development
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
SEP 11, 2022
Effects of Ketamine in Mice Depend on Sex of Human Experimenter
Researchers found that mice more consistently experience antidepressant effects from ketamine when administered by men a ...
SEP 30, 2022
Coronavirus
A New Kind of Antiviral Against SARS-CoV-2
SEP 30, 2022
A New Kind of Antiviral Against SARS-CoV-2
Scientists are developing a human version of a drug that was highly beneficial to a hamster model of COVID-19. The drug, ...
Loading Comments...